Boehringer Ingelheim’s Telmisartan preserves renal function in hypertensive patients with type 2 diabetic nephropathy
Document ID: PC-PH-103128
18/08/2022
Author: Boehringer Ingelheim
Related content
PC-PH-103128
Production date: August 2022
Production date: August 2022
Telmisartan (Micardis®) Important Safety Information
The overall incidence of adverse events reported with telmisartan (41.4%) was usually comparable to placebo (43.9%) in controlled clinical trials in patients treated for hypertension. The incidence of adverse events was not dose related and showed no correlation with gender, age or race of the patients. The safety profile of Telmisartan (Micardis®) in patients treated for prevention of cardiovascular morbidity and mortality was consistent with that obtained in hypertensive patients. For further details, please refer to the full prescribing information.
Telmisartan + HCTZ (Micardis Plus®) Important Safety Information
The overall incidence of adverse events reported with Telmisartan + HCTZ (Micardis Plus®) was comparable to those reported with telmisartan alone in randomised controlled trials involving 1471 patients receiving telmisartan plus hydrochlorothiazide (835) or telmisartan alone (636). There was no dose-relationship to undesirable effects and there was no correlation with gender, age or race of the patients. For further details, please refer to the full prescribing information.
Telmisartan + Amlodipine besilate (Twynsta®) Important Safety Information
The safety and tolerability of Telmisartan + Amlodipine besilate (Twynsta®) has been evaluated in five controlled clinical studies with over 3500 patients, over 2500 of whom received telmisartan in combination with amlodipine. Peripheral oedema, a recognised dose dependent side effect of amlodipine, was generally observed at a lower incidence in patients who received the telmisartan/amlodipine combination than in those who received amlodipine alone. For further details, please refer to the full prescribing information.
References
1. Joel MN, et al. J Clin Hypertens 2003;1:58-63
2. Michel M, et al. Pharmacol Rev 2013;65:809-848
3. Kakuta H, et al. Int J Clin Pharmacol Res 2005;25:41-46
4. Individual product labels accessed Dec 2012 (http://www.ema.europa.eu)
5. Bakris G, et al. Kidney Int 2008;DOI:10.1038/ki 2008.204
6. The ONTARGET Investigators. N. Eng J Med 2008;358(15):1547-1559
7. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N. Eng J Med 2000;342(3):145-153
8. Bramley TJ, et al. J Manag Care Pharm 2006;12(3):239-245
9. Mazzaglia G, et al. Circulation 2009;120:1598-1605
10. Matchar D, et al. Ann Intern Med 2008;148:16-29